There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...
Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...
About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...
REGENXBIO completes pivotal enrollment and initiates commercial production in Duchenne gene therapy programme: Rockville, Maryland Friday, October 31, 2025, 18:00 Hrs [IST] REGENX ...
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
TipRanks on MSN
Genprex Announces Securities Purchase Agreement and Offering
Genprex ( ($GNPX) ) has issued an announcement. On October 28, 2025, Genprex, Inc. announced a securities purchase agreement for a registered ...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced ...
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback